Evolution of World Journal of Clinical Cases over the past 5 years

Analysis of the articles published in any journal is necessary to ascertain the performance of the journal in the academia. The author made a scientometric analysis of the articles published in the World Journal of Clinical Cases in the past 5 years and present the data to the readers.     

Comparative Evaluation of Maxillary and Mandibular Anterior Teeth Width with the Length of Index and Little Finger

The size, color, morphology and arrangement of the anterior tooth are the various factors play an imperative role in achieving excellent esthetics in complete denture. Various modalities have been suggested for selecting the size of the anterior teeth like inter-alar distance, inter-canthal distance, bi-zygomatic width, intercanine width. There is no reliable method for selection of anterior teeth etc. To evaluate and compare the width of the maxillary and mandibular anterior teeth with the length of the index and little fingers. total of 50 people were taken for this study. They are grouped into four, Group I, 15–20 years; Group II, 20–30 years; Group III, 30–40 years; Group IV, 40–50 years. Irreversible hydrocolloid impressions of the maxilla and mandible were made and poured with dental stone. The widths of the maxillary and mandibular anterior teeth were measured with an adaptable ruler. The length of the index and little fingers were measured using a vernier caliper. There is significant correlation between the maxillary and mandibular anterior teeth with the index and little finger length. Conclusion: The maxillary anterior teeth width can be calculated with the formula (1.130 × index finger length − 11.972), mandibular anterior teeth width can be calculated with the formula (1.006 × little finger length − 2.231).     

Phase II trial of aflibercept with FOLFIRI as a second‐line treatment for Japanese patients with metastatic colorectal cancer

Aflibercept targets vascular endothelial growth factor. The present study involved assessing the efficacy, safety and pharmacokinetics of aflibercept plus 5‐fluorouracil/levofolinate/irinotecan (FOLFIRI) as a second‐line treatment for metastatic colorectal cancer (mCRC) in Japanese patients. Aflibercept (4 mg/kg) plus FOLFIRI was administered every 2 weeks in 62 patients with mCRC until disease progression, unacceptable toxicity or patient withdrawal. Tumors were imaged every 6 weeks. The primary endpoint was objective response rate (ORR); secondary endpoints were progression‐free survival, overall survival, safety, and pharmacokinetics of aflibercept, irinotecan and 5‐fluorouracil. A total of 60 patients were evaluated for ORR; 50 had received prior bevacizumab. The ORR was 8.3% (95% confidence interval [CI]: 1.3%‐15.3%), and the disease control rate (DCR) was 80.0% (69.9%‐90.1%). The median progression‐free survival was 5.42 months (4.14‐6.70 months) and the median overall survival was 15.59 months (11.20‐19.81 months). No treatment‐related deaths were observed, and no significant drug‐drug interactions were found. The most common treatment‐emergent adverse events were neutropenia and decreased appetite. Free aflibercept had a mean maximum concentration (coefficient of variation) of 73.2 μg/mL (15%), clearance of 0.805 L/d (22%) and volume of distribution of 6.2 L (18%); aflibercept bound with vascular endothelial growth factor had a clearance of 0.162 L/d (9%) (N = 62). Aflibercept did not significantly affect the pharmacokinetics of irinotecan or 5‐fluorouracil: The clearance was 11.1 L/h/m² (28%) for irinotecan and, at steady state, 72.6 L/h/m² (56%) for 5‐fluorouracil (N = 10). Adding aflibercept to FOLFIRI was shown to be beneficial and well‐tolerated in Japanese patients with mCRC. ClinicalTrials.gov Identifier: NCT01882868.     

Gestational weight gain and pregnancy outcomes: Findings from North Indian pregnancy cohort

Despite the high prevalence of inadequate gestational weight gain (GWG) and adverse pregnancy outcomes, very few studies have addressed the association between GWG and pregnancy outcomes in South Asia. Our objectives were to estimate the prevalence of GWG during the second and third trimesters within, below and above the Institute of Medicine (IOM) guidelines, and to estimate the effect of the rate and adequacy of GWG on gestational age at the time of delivery, weight, length, length-for-age z-score (LAZ), weight-for-length z-score (WLZ) and adverse pregnancy outcomes, namely prematurity, small-for-gestational age (SGA), low birth weight (LBW), stunting and wasting at birth. We analysed data from the intervention group of the Women and Infants Integrated Interventions for Growth Study (WINGS), which is an ongoing individually randomized factorial design study. Of the 1332 women analysed, 40.2% [95% confidence interval (CI) 37.5 to 42.8] had GWG below the IOM guidelines. For every 100-g/week increase in GWG, birth weight increased by 61 g, birth length by 0.16 cm, LAZ score by 0.08 SD, WLZ score by 0.14 SD, and gestational age at birth by 0.48 days. Women with GWG below the IOM guidelines had a higher relative risk of adverse pregnancy outcomes (44% for LBW, 27% for SGA, 32% for stunting and 42% for wasting at birth) than women who had GWG within the IOM guidelines, except for prematurity. The association between GWG and LAZ scores at birth was modified by early pregnancy body mass index (BMI). GWG is a strong predictor of newborn anthropometric outcomes and duration of gestation but not prematurity.     

Thyrotoxicosis after matched unrelated bone marrow transplantation

Acquired hyperthyroidism is most commonly autoimmune in etiology. In the setting of allogeneic bone marrow transplantation (BMT), the use of radiotherapy (total body irradiation) as part of the regimen prior to BMT is known to cause endocrine dysfunction, especially hypopituitarism and hypothyroidism, but hyperthyroidism is rare. The authors report this unusual and late complication in a young boy after BMT for relapsed childhood lymphoblastic leukemia and discuss the possible etiologies.